Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at Pinnacle Surgery Center in Austin, Texas, by ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...

The first prostate ablation treatment with the Ablatherm Robotic HIFU was performed at the Gramercy Surgery Center in New York. 1. Ivan Grunberger, MD, chief of urology at New York Methodist Hospital ...

— Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

An expert answered CURE® readers’ questions on several aspects of a prostate cancer journey, including treatment options and sexual function. A prostate cancer journey can involve plenty of questions.

Charlotte, N.C.-based SonaCare Medical earned clearance from the Food and Drug Administration for a new version of its Sonablate device. Sonablate, intended for use in the focused ablation of prostate ...